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O
ver 5,000 rare diseases have 
been described, the vast 
majority being of genetic 
origin. Rare diseases affect a small 
number of individuals—less than 
one person per 2,000, according to 
the European deﬁ  nition, or less than 
200,000 individuals in the United States, 
according to the US deﬁ  nition [1]. 
The few available epidemiological 
data are too limited to give ﬁ  rm 
details on the number of patients 
with a speciﬁ  c rare disease. Some rare 
diseases, such as cystic ﬁ  brosis, are 
relatively frequent and well known to 
the general public, but many diseases 
are extremely rare, affecting only a few 
patients. Although individually rare, 
these diseases affect collectively about 
30 million Europeans and 25 million 
North Americans. Such diseases, 
therefore, represent a major public-
health concern, especially considering 
that a large percentage of these severe 
diseases are life threatening or cause 
chronic illness, with a major impact 
on quality of life. Many of these rare 
diseases share common characteristics 
such as a lack of scientiﬁ  c and 
medical knowledge about the disease, 
diagnostic tools, and appropriate 
treatment, leading affected patients to 
relative isolation. 
For many rare diseases with a 
signiﬁ  cant health burden—such as 
ataxia telangiectasia, Usher syndrome, 
progeria, and amyotrophic lateral 
sclerosis—there is simply no speciﬁ  c 
treatment for the disease. The 
development of treatments faces two 
hurdles: the lack of understanding 
of underlying pathophysiological 
mechanisms and the lack of interest 
from the pharmaceutical industry in 
rare diseases. Indeed, the high cost of 
drug development, together with the 
estimated low return on investment 
(due to very small patient populations), 
has discouraged the pharmaceutical 
industry from developing drugs for rare 
diseases, despite the huge medical need.
The Need for Incentives
Some hope arose from the “orphan 
drug” concept (i.e., drugs for rare 
diseases that have inadequate 
treatments) and regulations designed 
to stimulate development of such 
orphan drugs by providing assistance 
and economic incentives. The main 
incentive is probably the promised 
marketing exclusivity of seven years 
in the United States [2] and ten years 
in Europe, beginning on the date of 
market approval, for products with an 
orphan designation. 
The ﬁ  rst country to propose such 
a legal framework was the US, with 
the US Orphan Drug Act (1983) [3], 
followed by Japan in 1993, Australia in 
1998, and Europe in 1999 [4]. These 
orphan drug regulations have proved 
their success, particularly in certain 
ﬁ  elds (oncology, immunology, and 
metabolic disorders) [2,5]. Since the 
implementation of the US Orphan 
Drug Act, 1,432 drugs and biological 
products have been designated as 
orphan products, and 266 orphan 
products have received marketing 
approval from the US Food and Drug 
Administration. In Europe, only four 
years after implementation of the 
European orphan regulation [4], 271 
products have been designated and 
18 products have received marketing 
authorization. Moreover, as a result 
of the orphan regulations, several 
biotechnology ﬁ  rms have been created 
to develop treatments for rare diseases.
Intensifying Therapeutic Research
Although orphan drug regulations have 
certainly facilitated the development 
of treatments for rare diseases, major 
difﬁ  culties still persist and additional 
initiatives are needed. As mentioned, 
one of the main obstacles is the lack of 
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Box 1. European Research 
Institutions and Organizations 
Supporting ERDITI
• The Medical University of Vienna
• Belgium Fund for Scientiﬁ  c Research
• Danish Medical Research Council
• French National Center for Scientiﬁ  c 
Research
• French National Institute of Health and 
Medical Research
• German Aerospace Center Project 
Management Organizations–Health 
Research
• The Netherlands Organization for Health 
Research and Development
• Dutch Steering Committee on Orphan 
Drugs
• The Croatian Academy of Sciences and 
Arts
• The Spanish Institute for Research on 
Rare Diseases 
• Slovak Academy of SciencesPLoS Medicine  |  www.plosmedicine.org 0846
understanding of the pathophysiology 
of many rare diseases. Since the 
identiﬁ  cation of therapeutic targets 
largely depends on the genetic and 
molecular characterization of the 
diseases and on the elucidation of 
biological mechanisms, it is crucial 
to intensify clinical, genetic, and 
pathophysiological research on rare 
diseases [1]. There is, thus, a pressing 
need to increase the public research 
effort at national and international 
levels.
With advances in research, 
sequencing of the human genome, 
and development of high-throughput 
genomic and post-genomic tools, 
we may expect that the mechanisms 
underlying many rare genetic disorders 
will be unraveled in the next few 
years. For these disorders, therapeutic 
research also needs to be promoted, 
including innovative biotechnological 
research (monoclonal antibodies, 
cell and gene therapy, and enzyme 
replacement therapy) as well as classical 
therapeutic research based on the 
search for active chemical compounds. 
Indeed, even in the ﬁ  eld of rare 
genetic disorders, selection of chemical 
compounds acting on identiﬁ  ed 
biological targets represents an 
important objective for drug discovery. 
Since in most cases pharmaceutical 
industries will not undertake this 
primary step, it is important to develop 
a public-sector interest in doing so.
Two strategies can be exploited to 
identify active chemical compounds. 
The ﬁ  rst strategy—widely applied 
by the pharmaceutical industry for 
drug discovery—is high-throughput 
screening of several thousands of 
compounds on biological targets. 
Such an approach is now possible 
within the academic sector thanks to 
the increased availability of public 
nonproprietary chemical libraries 
and screening facilities. This strategy 
requires development of a relevant 
biological assay that must be adapted to 
robotization. 
The second strategy—a more 
focused approach—is based on 
pathophysiological knowledge of the 
diseases, leading to identiﬁ  cation 
of therapeutic targets. Speciﬁ  cally 
designing new compounds seems very 
difﬁ  cult, given the very high costs 
involved, but the evaluation of existing 
chemical compounds with known 
biological activities represents a very 
interesting (and much less costly) 
option for therapeutic research. The 
thousands of compounds that have 
been developed by pharmaceutical 
companies for more common diseases 
but that were abandoned or failed to 
achieve registration for several reasons 
(such as biopharmaceutical properties, 
toxicity, lack of efﬁ  cacy, or strategic 
reasons) represent a treasure worth 
exploiting. The availability of such 
compounds could allow us to shortcut 
the traditional route of pharmaceutical 
development and evaluate swiftly—at 
minimal costs—drug candidates for the 
treatment of rare diseases.
Toward a Public–Private 
Partnership
The challenge is thus to manage the 
interface between pharmaceutical 
companies and traditional public-
sector organizations by establishing a 
public–private collaboration, leading to 
the evaluation of these drug candidates 
in the ﬁ  eld of rare diseases. Such a 
partnership between public research 
organizations and private companies 
has now been established. It is called 
European Rare Diseases Therapeutic 
Initiative (ERDITI) (http:⁄⁄www.
erditi.org), and it has three main 
objectives: (1) to provide academic 
teams with facilitated access to available 
compounds developed by companies, 
(2) to provide a streamlined facilitated 
process of collaboration between 
public and private partners, and (3) to 
guarantee continuity all the way from 
preclinical research to development 
and commercialization of the drug. 
ERDITI is sponsored by the 
European Science Foundation and is 
coordinated by the French Institute for 
Rare Diseases Research. This institute 
is an informal organization, grouping 
the ministries in charge of research, 
health, and industry, the French 
National Institute for Health and 
Medical Research, the French National 
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Figure 1.How ERDITI Functions as a Public–Private Partnership
The working procedure guarantees continuity all the way from research to development of a 
drug. After the ERDITI scientiﬁ  c advisory board’s assessment of the request, industry partners are 
questioned about the availability of molecules belonging to the pharmacological classes of interest. 
Several molecules may be of strategic interest for the industry partner, and sponsored research 
should be negotiated directly outside the framework of this working procedure. If there are no 
molecules available, the process ends. If molecules are available, a speciﬁ  c agreement is signed and 
the industry partner provides molecules required for preclinical studies. If promising results arise 
from preclinical studies, the lead academic partner asks the industry partner whether it wishes to 
exercise the option to further develop the drug. The industry partner may decide to exploit the 
results and develop one of the molecules through a worldwide exclusive license. Alternatively, the 
industry partner may decide not to exploit the results and grant necessary license rights to a third 
party for the development of the molecule for treating the rare disease.PLoS Medicine  |  www.plosmedicine.org 0847
Center for Scientiﬁ  c Research, patients’ 
organizations (French Muscular 
Dystrophy Association and French Rare 
Diseases Alliance), and public health 
insurance. Its goal is to foster research 
on rare diseases in France, but it also 
works at the European level. 
To date, four major pharmaceutical 
companies involved in research—
Aventis, GlaxoSmithKline, Roche, 
and Servier—and about ten European 
research institutions or organizations 
support ERDITI (Box 1). A ﬂ  exible 
management and coordination 
approach has been adopted (Figure 1). 
Any academic researcher conducting a 
project on a rare disease, or a group of 
rare diseases, who is willing to evaluate 
the therapeutic potential of chosen 
compounds for preclinical studies 
simply needs to apply to participate 
(at http:⁄⁄www.erditi.org). The 
suitability of the request is assessed 
by a scientiﬁ  c advisory committee, 
consisting of European experts from 
both academic and private sectors. 
After approval, pharmaceutical 
company partners are questioned on 
the availability of molecules belonging 
to pharmacological classes of interest. 
If a molecule (or several molecules) 
is available, a speciﬁ  c agreement is 
signed between the industry partner 
and the academic team. Then the 
industry partner provides reasonable 
quantities of the molecules required 
for preclinical studies, together with 
the necessary information about the 
molecules. Obviously, transactions 
with each pharmaceutical company 
partner are dealt with separately 
and in conﬁ  dentiality. It should 
be emphasized that requests must 
be based on a pathophysiological 
hypothesis, and that the partnership 
excludes high-throughput screening or 
the building of a common “non-used 
compounds” library.
A Charter of Collaboration
The ERDITI partnership is based on 
a charter of collaboration, including a 
standard agreement that describes the 
objectives of the research and deﬁ  nes 
the framework for the transfer and 
use of compounds. It also deﬁ  nes the 
rights and obligations of each party 
in terms of protection of information, 
intellectual property, and industrial 
property.
Obviously, intellectual property rights 
had to be clariﬁ  ed between academic 
and industrial partners. It has been 
agreed that the results originating from 
the study in the ﬁ  eld of rare diseases will 
be the sole property of the academic 
partner but may be freely used by the 
industry partner for internal research 
purposes. On the other hand, when 
research on the molecules supplied 
by the industry yields results that 
are applicable outside of the ﬁ  eld of 
rare diseases, these results shall be 
the pharmaceutical company’s sole 
property. In this case, if the industry 
partner wants to commercially exploit 
these results outside the ﬁ  eld of rare 
diseases, a royalty is negotiated by the 
public-sector partner. 
Another key point of the agreement 
is to guarantee that the project will 
continue from research to development 
in cases where preclinical studies 
uncover the potential of a chemical 
compound for treating a rare disease. 
Indeed, the industry partner who has 
rights to this drug will either develop 
the drug for the rare disease indication 
through a worldwide exclusive 
license agreement, or it will allow its 
development by an academic team or a 
third party (in which case the industry 
partner grants the necessary license 
rights for the drug’s development by a 
third party).
How Does Industry Beneﬁ  t?
One may wonder, what could be the 
beneﬁ  ts for industry of entering into 
such a partnership? For a few years 
now, some pharmaceutical companies 
have shown an interest in rare diseases 
for four reasons. Firstly, they seek 
an image of a “socially responsible 
company.” Secondly, some orphan 
products such as imatinib mesylate 
(Gleevec) or enzyme replacement 
therapies have clearly proved their 
proﬁ  tability. Thirdly, research on rare 
diseases may be proﬁ  table for more 
common diseases—several rare diseases 
might represent valuable proof-of-
concept models, and their study may 
repay research efforts by leading to the 
discovery of drugs for the treatment 
of more frequent diseases. Finally, 
ERDITI offers drug companies the 
chance to give new indications to 
abandoned compounds. 
We must make it clear that the 
industrial partners are not forced 
to supply compounds or to give any 
reason for refusal. The authenticity of 
their commitment will be measured 
in the future only by concrete results, 
which means by the extent to which 
they make compounds available 
for therapeutic research projects. 
However, the commitment of the four 
pharmaceutical companies already 
involved with ERDITI—who are willing 
to take up the challenge and to open 
their compound libraries to academic 
therapeutic research—really raises 
hope for future development of new 
drugs. 
The Coming Challenges
To ensure the success of this public–
private partnership, it needs to be 
better publicized within the scientiﬁ  c 
community. Indeed most European 
scientists are not aware of this initiative, 
because of a lack of information about 
it within universities and research 
institutions. 
The issue of funding for research 
projects is also an important challenge. 
ERDITI does not provide any direct 
additional funding mechanism for 
research, and so researchers must obtain 
funds from their customary sources for 
their preclinical projects. In France, 
some speciﬁ  c funding incentives have 
been established but this effort must be 
strengthened. At the European level, 
the challenge will be to establish and 
fund a public–private platform for rare 
diseases that achieves two things: (1) the 
ability to identify and fund promising 
preclinical projects and (2) the 
development of clinical multicentered 
projects through provision of the 
necessary expertise and funding. 
Once we have shown that ERDITI 
is a feasible initiative, we intend to 
Related Web Sites
• European Medicines Agency Committee 
for Orphan Medicinal Products: http://
www.emea.eu.int/htms/human/comp/
compsumop.htm
• US Food and Drug Administration Ofﬁ  ce 
of Orphan Products Development: http://
www.fda.gov/orphan
• Orphanet (a database dedicated to 
information on rare diseases and orphan 
drugs): http://www.orpha.net/
September 2005  |  Volume 2  |  Issue 9  |  e243
Some orphan products 
have proved their 
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open ERDITI to other pharmaceutical 
companies or biotechnology societies, 
and to broaden its scope to a more 
global partnership.  
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